Yamamoto I - Search Results

1

Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes.

Jiang R, Yamaori S, Takeda S, Yamamoto I, Watanabe K. Jiang R, et al. Among authors: yamamoto i. Life Sci. 2011 Aug 1;89(5-6):165-70. doi: 10.1016/j.lfs.2011.05.018. Epub 2011 Jun 16. Life Sci. 2011. PMID: 21704641

2

Structural requirements for potent direct inhibition of human cytochrome P450 1A1 by cannabidiol: role of pentylresorcinol moiety.

Yamaori S, Okushima Y, Masuda K, Kushihara M, Katsu T, Narimatsu S, Yamamoto I, Watanabe K. Yamaori S, et al. Among authors: yamamoto i. Biol Pharm Bull. 2013;36(7):1197-203. doi: 10.1248/bpb.b13-00183. Biol Pharm Bull. 2013. PMID: 23811569 Free article.

3

Cannabidiol induces expression of human cytochrome P450 1A1 that is possibly mediated through aryl hydrocarbon receptor signaling in HepG2 cells.

Yamaori S, Kinugasa Y, Jiang R, Takeda S, Yamamoto I, Watanabe K. Yamaori S, et al. Among authors: yamamoto i. Life Sci. 2015 Sep 1;136:87-93. doi: 10.1016/j.lfs.2015.07.007. Epub 2015 Jul 15. Life Sci. 2015. PMID: 26187180 Free article.

4

Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19.

Jiang R, Yamaori S, Okamoto Y, Yamamoto I, Watanabe K. Jiang R, et al. Among authors: yamamoto i. Drug Metab Pharmacokinet. 2013;28(4):332-8. doi: 10.2133/dmpk.dmpk-12-rg-129. Epub 2013 Jan 15. Drug Metab Pharmacokinet. 2013. PMID: 23318708 Free article.

5

Cannabidiol-2',6'-dimethyl ether, a cannabidiol derivative, is a highly potent and selective 15-lipoxygenase inhibitor.

Takeda S, Usami N, Yamamoto I, Watanabe K. Takeda S, et al. Among authors: yamamoto i. Drug Metab Dispos. 2009 Aug;37(8):1733-7. doi: 10.1124/dmd.109.026930. Epub 2009 Apr 30. Drug Metab Dispos. 2009. PMID: 19406952

6

Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol.

Yamaori S, Okushima Y, Yamamoto I, Watanabe K. Yamaori S, et al. Among authors: yamamoto i. Chem Biol Interact. 2014 May 25;215:62-8. doi: 10.1016/j.cbi.2014.03.007. Epub 2014 Mar 22. Chem Biol Interact. 2014. PMID: 24667653 Free article.

7

Involvement of human blood arylesterases and liver microsomal carboxylesterases in nafamostat hydrolysis.

Yamaori S, Fujiyama N, Kushihara M, Funahashi T, Kimura T, Yamamoto I, Sone T, Isobe M, Ohshima T, Matsumura K, Oda M, Watanabe K. Yamaori S, et al. Among authors: yamamoto i. Drug Metab Pharmacokinet. 2006 Apr;21(2):147-55. doi: 10.2133/dmpk.21.147. Drug Metab Pharmacokinet. 2006. PMID: 16702735 Free article.

8

Major cytochrome P450 enzymes responsible for microsomal aldehyde oxygenation of 11-oxo-Delta8-tetrahydrocannabinol and 9-anthraldehyde in human liver.

Watanabe K, Matsunaga T, Kimura T, Funahashi T, Funae Y, Ohshima T, Yamamoto I. Watanabe K, et al. Among authors: yamamoto i. Drug Metab Pharmacokinet. 2002;17(6):516-21. doi: 10.2133/dmpk.17.516. Drug Metab Pharmacokinet. 2002. PMID: 15618706 Free article.

9

Comparison in the in vitro inhibitory effects of major phytocannabinoids and polycyclic aromatic hydrocarbons contained in marijuana smoke on cytochrome P450 2C9 activity.

Yamaori S, Koeda K, Kushihara M, Hada Y, Yamamoto I, Watanabe K. Yamaori S, et al. Among authors: yamamoto i. Drug Metab Pharmacokinet. 2012;27(3):294-300. doi: 10.2133/dmpk.dmpk-11-rg-107. Epub 2011 Dec 13. Drug Metab Pharmacokinet. 2012. PMID: 22166891 Free article.

10

Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6.

Yamaori S, Okamoto Y, Yamamoto I, Watanabe K. Yamaori S, et al. Among authors: yamamoto i. Drug Metab Dispos. 2011 Nov;39(11):2049-56. doi: 10.1124/dmd.111.041384. Epub 2011 Aug 5. Drug Metab Dispos. 2011. PMID: 21821735

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results